Carnegie Investment Counsel Boosts Holdings in CME Group Inc. (NASDAQ:CME)

Carnegie Investment Counsel boosted its position in shares of CME Group Inc. (NASDAQ:CME) by 0.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 9,557 shares of the financial services provider’s stock after purchasing an additional 75 shares during the quarter. Carnegie Investment Counsel’s holdings in CME Group were worth $1,879,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of CME. First Citizens Bank & Trust Co. lifted its stake in CME Group by 1.7% during the 2nd quarter. First Citizens Bank & Trust Co. now owns 35,755 shares of the financial services provider’s stock valued at $7,029,000 after acquiring an additional 610 shares during the period. Hennion & Walsh Asset Management Inc. lifted its stake in shares of CME Group by 40.8% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 10,742 shares of the financial services provider’s stock worth $2,112,000 after purchasing an additional 3,112 shares during the period. MONECO Advisors LLC boosted its holdings in shares of CME Group by 22.9% in the second quarter. MONECO Advisors LLC now owns 1,458 shares of the financial services provider’s stock worth $287,000 after buying an additional 272 shares during the last quarter. Demars Financial Group LLC grew its position in CME Group by 4.4% during the second quarter. Demars Financial Group LLC now owns 2,057 shares of the financial services provider’s stock valued at $404,000 after buying an additional 87 shares during the period. Finally, Raymond James & Associates increased its holdings in CME Group by 3.2% during the second quarter. Raymond James & Associates now owns 3,029,145 shares of the financial services provider’s stock valued at $595,530,000 after buying an additional 94,302 shares during the last quarter. 87.75% of the stock is currently owned by institutional investors.

CME Group Stock Down 0.1 %

Shares of NASDAQ CME traded down $0.17 during trading hours on Tuesday, hitting $208.70. 807,456 shares of the stock were exchanged, compared to its average volume of 1,935,332. CME Group Inc. has a 12 month low of $190.70 and a 12 month high of $223.80. The firm has a fifty day moving average price of $198.74 and a 200-day moving average price of $207.08. The company has a quick ratio of 1.01, a current ratio of 1.02 and a debt-to-equity ratio of 0.10. The company has a market cap of $75.15 billion, a PE ratio of 23.75, a PEG ratio of 6.27 and a beta of 0.52.

CME Group (NASDAQ:CME) last announced its earnings results on Wednesday, July 24th. The financial services provider reported $2.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.03. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.53 billion. CME Group had a return on equity of 12.82% and a net margin of 56.98%. The firm’s quarterly revenue was up 12.7% compared to the same quarter last year. During the same period in the prior year, the company posted $2.30 EPS. On average, sell-side analysts expect that CME Group Inc. will post 9.8 EPS for the current year.

CME Group Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 25th. Shareholders of record on Monday, September 9th will be issued a $1.15 dividend. The ex-dividend date is Monday, September 9th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.20%. CME Group’s dividend payout ratio is currently 52.33%.

Insider Transactions at CME Group

In related news, Director Charles P. Carey sold 3,000 shares of the firm’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $195.44, for a total value of $586,320.00. Following the completion of the transaction, the director now owns 7,163 shares in the company, valued at approximately $1,399,936.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Charles P. Carey sold 3,000 shares of the company’s stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $195.44, for a total value of $586,320.00. Following the sale, the director now directly owns 7,163 shares of the company’s stock, valued at approximately $1,399,936.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel R. Glickman sold 650 shares of the company’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $201.44, for a total transaction of $130,936.00. Following the completion of the sale, the director now directly owns 14,008 shares in the company, valued at $2,821,771.52. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on CME shares. Piper Sandler reiterated an “overweight” rating and set a $225.00 target price on shares of CME Group in a research report on Tuesday. Rosenblatt Securities reiterated a “sell” rating and issued a $187.00 price target (up previously from $185.00) on shares of CME Group in a research note on Thursday, April 25th. JPMorgan Chase & Co. increased their price target on CME Group from $187.00 to $191.00 and gave the company an “underweight” rating in a research note on Thursday, July 25th. Bank of America boosted their price target on shares of CME Group from $209.00 to $216.00 and gave the stock a “neutral” rating in a research report on Thursday, April 25th. Finally, Barclays upped their price target on shares of CME Group from $208.00 to $209.00 and gave the stock an “equal weight” rating in a report on Thursday, July 25th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $213.27.

About CME Group

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.